VIM and non-small cell lung carcinoma: In our own retrospective study of 2066 patients with non-small cell lung cancer (NSCLC), the incidence of PSC was 2.6%, including biopsy specimens that showed various aspects of sarcomatoid differentiation (spindle cell or pleomorphic morphology, co-expression of the mesenchymal marker vimentin with high proliferative activity) [54].